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The AIDS epidemic has transformed the importance ofcytomegalovirus (CMV) as a pathogen
for the adult human central nervous system (CNS). At autopsy, about 25 percent ofAIDS cases
have cytopathologic evidence of CNS infection by CMV. Since almost nothing is known of the
host CNS-viral interactions, we havedeveloped a laboratory model ofCMV infection ofthe brain
in the guinea pig. In the present paper, we review the syndromes ofCMV infection ofthe human
CNS and compare the neuropathological findings of the opportunistic CMV brain infection in
AIDS with the model. Destructive meningoencephalitis, perivascular infiltrates, and subependy-
mal inflammation are found in both, but theglial nodule is the mostcharacteristic featureofeach.
Thus, we demonstrate that the model faithfully reflects the histopathology ofthe human disease.
Furthermore, since we have found that CNS infection is achieved following systemic infection in
the guinea pig, the model recapitulates the sequence ofinfection in humans.
INTRODUCTION
Prior to the AIDS epidemic, cytomegalovirus (CMV) was not a common pathogen
for the adult human central nervous system (CNS). The most important CMV
infection of the CNS was the syndrome of cytomegalic inclusion disease of newborn
infants. In adults, evidence for CMV infection of the CNS was largely restricted to
immunosuppressed patients, particularly allograft recipients. Cases in immunologi-
cally intact adults wereextremely rare, and thosewith documentation ofvirus isolation
from the CNS were rarer still.
Cytomegalic Inclusion Disease
Cytomegalic inclusion disease is a devastating multisystem viral infection acquired
in utero. Significant hepatic, splenic, and hematologic manifestations occur in addition
to CNS involvement [1]. Neurological manifestations include mental retardation,
spasticity, and seizures. On gross examination ofthe brain, microcephaly, ventricular
enlargement, cortical atrophy, and polycysticencephalomalacia maybe found [2]. The
brunt ofthe CNS disease is borne by the subependymal germinal matrix ofthe lateral
ventricles; however, the majority of infants congenitally infected with CMV are
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asymptomatic at birth. Nonetheless, there is evidence forvariable intellectual dysfunc-
tion and hearing loss in prospectively studied infants positive for IgM antibody at birth
[3]. Hence, there is a rangeofneurologic dysfunction associated with congenital CMV
infection, of which cytomegalic inclusion disease is the most severe and most easily
recognized.
Allograft and Tumor Immunosuppression
In 1965, Schneck reported neuropathological evidence of CMV infection in the
brains ofpatients who had undergone renal transplantation [4]. In 34 transplant cases,
11 were found to have glial nodules, among whom two were also found to have
intranuclear inclusions. No clinical syndrome was identified. Similarly, Dorfman
commented on the difficulty of making a diagnosis of cytomegalovirus encephalitis in
renal allograft recipients because of the potential multiple causes of diffuse encepha-
lopathy [5]. Furthermore, the cerebrospinal fluid (CSF) was normal in three of the
four cases reported by him. In lethal CMV infection following renal transplantation,
the brain is only one of several organs to have evidence of infection [6]. Evidence for
CMV infection of the brain has also been reported following other causes of
immunosuppression. For example, Koeppen et al. have reported the case of a
51-year-old man treated with chemotherapy for a small-cell undifferentiated lym-
phoma who experienced severe neurological disease and blindness [7]. Autopsy
revealed inclusion body retinitis, multiple CNS infarcts associated with occlusive
arteritis, and inclusion-bearing cells around foci of necrosis. Hence CMV infection of
the CNS may occur in the setting ofvarious causes ofimmunosuppression.
Immunocompetent Adults
Clinically apparent CMV infection ofthe CNS in immunocompetent adults appears
to be a very rare event and the diagnosis difficult to establish. CMV antibody levels
fluctuate within normal individuals [8], and CMV replication may be stimulated by a
variety of nonspecific immunological challenges. Reliance on serum antibody titers or
isolation of the virus outside the CNS, such as from the urine, may be misleading
because these may not correlate with the presence ofCMV in the brain. Fourofthe six
previously reported cases reviewed by Siegman-Igra et al. relied on serum antibody or
virus isolation away from the CNS for diagnosis [9]. Their own case demonstrated a
serum antibody rise and the presence of antibody in undiluted CSF. More secure
diagnostic findings include local production of anti-CMV antibody in the CSF, and
virus isolation from the CSF or the brain. Phillips et al. have reported two cases in
immunologically competent adults with CNS viral isolates [10]. CMV was isolated
from the CSFofa 52-year-old male with headaches, seven whitecells in the CSF, mild
right arm weakness, a clouded sensorium, and focal electroencephalogram (EEG)
slowing. The second case was that of a 20-year-old woman in whom headache, fever,
seizures, CSF pleocytosis, focal EEG abnormalities, and progressive neurologic
dysfunction prompted a brain biopsy from which CMV was isolated. Histologically the
biopsy revealed microglial and astrocytic proliferation. Both cases demonstrated
improvement following treatment with vidarabine.
AIDS
As of 1981, at the start of the acquired immunodeficiency syndrome (AIDS)
epidemic, CMV was regarded as a pathogen for the fetal CNS and the CNS of
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immunocompromised patients, primarily renal allograft recipients. After the start of
the epidemic, two facts became clear. First, disseminated CMV infection was the rule
in AIDS patients [11] and, second, neurologic complications in AIDS were common
[12]. Subsequently, large neuropathological autopsy studies revealed that CMV was
the most common opportunistic infection of the CNS in AIDS [13,14]. There have,
however, been a variety of clinical-pathological manifestations associated with CMV
infection ofthe CNS, ranging from asymptomatic infection to necrotizing encephalitis
[15,16]. Furthermore, little is known of the important host-viral interactions which
facilitate CMV brain infection, due in no small part to the absence of a well-
characterized animal model. Hence we have developed an experimental model ofCMV
encephalitis in the guinea pig [17,18]. Because of the principal neuropathologic
feature, as in the human infection, we have termed the model glial nodule encephalitis.
In this section, we review the current state ofknowledge ofCMV encephalitis in AIDS
patients and in the following section compare the neuropathological characteristics of
the opportunistic infection in AIDS patients with the animal model.
Separationfrom the AIDS Dementia Complex
Soon after the onset of the AIDS epidemic, Snider et al. defined many of the
neurological complications seen in AIDS patients [12]. Prominent among these
conditions was subacute encephalitis (subacute encephalopathy) manifested by psy-
chomotor retardation and progressing over weeks or months to severe dementia. Based
on the presence ofdisseminated CMV and histopathologic findings such as microglial
nodules and inclusions, the authors proposed that CMV might be the cause of this
syndrome. Nielsen et al. supported the role of CMV in the subacute encephalitis based
on similar autopsy findings in 19 patients [19]; however, in 1985, Shaw et al.
demonstrated the presence of HTLV-III (HIV) by in situ hybridization in five of 15
cases [20]. Richard Price and his colleagues performed a careful clinical and
pathological analysis to demonstrate that this was a new entity, most probably due to
HIV itself, which they termed the AIDS dementia complex [21-23]. These investiga-
tors analyzed autopsy material from demented patients according to the presence of
multinucleated cells and also the number of microglial nodules [23]. In the subgroup
characterized by the absence of multinucleated cells and the presence of abundant
microglial nodules, nine of ten cases had cytomegalic inclusions; however, these
findings bore no anatomic relationship to white matter pallor and vacuolation, which
the authors viewed as key to the pathogenesis ofthe clinical syndrome. Thus the AIDS
dementia complex, as defined by Navia and Price and their colleagues, is based on
white matter and subcortical changes and is thought to result from HIV infection of
the brain.
Clinical Manifestations ofCMVEncephalitis in AIDS
Studies based on histopathologic evidence for CMV, principally cytomegalic
inclusion-bearing cells, reveal a spectrum of associated neurological disorders. In a
retrospective review of AIDS cases found at autopsy to have evidence for CMV, Post
and her colleagues identified progressive encephalopathy as a common presentation
[24]. Morgello et al. found that dementia was present in cases with CMV infection
characterized by either glial nodules or focal parenchymal necrosis [15]. In addition to
dementia, a heterogeneous group of clinical conditions associated with CMV infection
of the brain in AIDS patients emerges on review of the literature. The clearest
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clinical-pathological correlation of CMV infection in the report of Morgello and her
colleagues was necrotizing radiculomyelitis presenting clinically as ascending my-
elopathy [15]. Illustrative case material presented by Vinters et al. displayed a wide
range ofclinical manifestations [16]. These included progressive confusion and mental
status deterioration, myelopathy, focal cerebral dysfunction, and meningoradiculitis.
The authors commented on the heterogeneous nature of CMV-associated pathology,
and the coexistence of other pathological processes, including evidence for co-
localization of HIV and CMV.
In addition to retrospective clinical pathological analysis, response to antiviral
therapy has been used tocharacterize CMV-associated CNS syndromes. Masdeu et al.
have reported the case of a 43-year-old male AIDS patient with multifocal CNS
dysfunction which was shown by stereotactic biopsy to be caused by CMV [25].
Experimental antiviral therapy with a guanine derivative (BWB759U) was associated
with improvement of focal neurological signs and a decrease in the size of the lesions
found on magnetic resonance imaging. Fiala et al. have reported clinical improvement
with the use of the anti-CMV agent 9-(1,3-dihydroxy-2-propoxymethyl) guanine
(DHPG) in two cases of acute meningoencephalitis [26]. These authors also
commented that CMV might augment HIV by increasing the lysis of cells doubly
infected with HIV and CMV.
CMVas a Cofactorfor HIV
There are pathological and virological data supporting the possibility of CMV
serving as a cofactor for HIV infection ofthe brain. Vinters et al. have found evidence
for human immunodeficiency virus (HIV) in close proximity to CMV in several cases
ofCMV infection ofthe CNS in AIDS [16]. Using several double-labeling techniques,
Nelson et al. have shown a significant incidence ofdouble infection, HIV and CMV, in
single cells in the CNS ofAIDS patients [27].
There are at least three mechanisms whereby CMV could serve as a cofactor for
HIV (Table 1). According to the "Trojan horse" theory, HIV-infected circulating
monocytes bring HIV into the brain [28]. CMV infection of the brain, whether
transient or established, could serve as a cofactor by attracting HIV-infected mono-
cytes. A second mechanism is the provision of a transactivation protein by CMV to
enhance HIV replication [27]. Yet another mechanism is immunological. HIV
depletes the CD4 helper-inducer subset of T cells, and CMV induces nonspecific
immunosuppression mediated by monocytes [29]. Together, the combined immuno-
suppression may facilitate infection ofthe brain by one or both agents.
GUINEA PIG MODEL
There are many fundamental questions concerning CMV infection of the CNS
about which little is known. For example, it it not known how the CNS is infected
during the course of systemic infection, the frequency of clinically inapparent
infection, the mechanisms of host defense to prevent CNS infection, and the mecha-
nisms which clear CMV once the CNS has been infected. These and other questions of
viral-host interaction must be addressed if a logical approach is to be made in
preventing and treating CMV encephalitis in AIDS patients. In light of the extensive
experience with the guinea pig CMV model in these laboratories [30], we sought to
determine whether the model could be extended to study CMV encephalitis.
Following intracerebral (i.c.) inoculation ofyoung guinea pigs, it was found that the
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TABLE1
Potential Roles for CMV as a Cofactor for HIV Infection of the Brain
1. Attract monocytes to the brain and stimulate differentiation of macrophages
2. Provision of transactivation
3. Co-suppression of immune function
a. HIV-CD4 depletion
b. CMV-Monocyte-mediated immunosuppression
titer of CMV peaked in the brain in the first week after inoculation [17]. Virus was
cleared at three to four weeks, about the time of development of serum-neutralizing
antibody. Leptomeningitis developed and peaked in the first week of infection,
independent ofchanges in the brain parenchyma. On cytochemical study, it was found
that the predominant cell in the leptomeningitis belonged to the monocyte-macrophage
series [18]. Parenchymal changes peaked in the second week post-infection. At higher
viral doses i.c., meningoencephalitis with necrosis was found [17]. Both Morgello et al.
[15] and Vinters et al. [16] have reported necrotizing encephalitis in the human
disease. In the example shown in Fig. 1, taken at autopsy from a patient with AIDS,
necrotizing encephalitis with florid inclusion-bearing cells is demonstrated. Macro-
phages, microglia, and astrocytes were found within the intact parenchyma, whereas
abundant macrophages were present in necrotic material. A similar pattern has been
observed in the guinea pig, except that lesions with very abundant inclusion-bearing
cells have not been observed.
The most characteristic finding in the parenchyma in CMV encephalitis, in humans
and in the guinea pig model, is the glial nodule (Fig. 2A). It was found in all 30 cases by
Morgello and her colleagues [15] and in 28 of the 30 cases studied by Vinters and his
colleagues [16]. The nodules consist of collections of cells, often in a swirled pattern,
which appear by histologic criteria to be microglia (rod cells) and macrophages. They
are found to be associated with intranuclear inclusion-bearing cells in a low percentage
ofobservations in both the model and the human disease. In the model, the majority of
cells, both round and rod cells, reacted positively with a histochemical stain for
macrophages [18]. This observation is compatible with data showing that microglia
are related to monocytes and macrophages [31]. No T cells were identified in the glial
nodules [18]. Thus, we found that the host defense response to CMV infection of the
CNS in the guinea pig was dominated by cells belonging to the monocyte series.
Another characteristic parenchymal lesion, subependymal inflammation, is seen in
both the human and model (Fig. 2B) diseases. It will be recalled that this is a primary
region of pathology in cytomegalic inclusion disease of infants (see above). In both the
guinea pig and human, ventriculitis and ventriculoencephalitis can also be observed.
CNS vasculitis, manifested by inflammatory cells in the vessel wall, is found in the
human disease and in the model. While demyelination has been reported in CMV
infection ofthe CNS in AIDS [32], the observation has not been made consistently and
remains anecdotal [16]. In all consistent features then, the model reflects the changes
in the human brain.
In recent studies, we have extended our observations to infection of the brain
following peripheral inoculation [Booss J, Griffith BP, Kim JH: manuscript in
preparation]. Two types of evidence for viral infection of the brain were present
following intraperitoneal (i.p.) infection. Dependent on the virus inoculum, both
histopathologic changes and virus isolation, or histopathologic changes alone, were
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FIG. 2. CMV encephalitis in the guinea
pig model. A. A microglial nodule
composed of loosely arranged microglial
cells and scattered round inflammatory
cells. Guinea pig sacrificed 14 days after
intraperitoneal infection with 104 TCID50.
Hematoxylin and eosin stain. Magnifica-
tion x 420. B. Focal infiltration of
round nuclear inflammatory cells in the
periventricular region. An arrowhead indi-
cates the point of a sudden transition
between inflammatory cell-infiltrated and
normal-appearing periventricular regions.
Guinea pig sacrificed 13 days after intra-
peritoneal infection with 106 TCID50. V,
ventricle. Hematoxylin and eosin stain.
Magnification x 90.
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observed. Incontrast to i.c. inoculation, leptomeningitis was minimal, but parenchymal
changes were similar (Fig. 2). The guinea pig model thus offers the opportunity to
study mechanisms ofbrain infection following systemic infection and the mechanisms
of host defense in the brain. These observations could provide the basis for logical
prevention and therapy ofCMV infections ofthe CNS in AIDS patients.
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